Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04246463

Terumo Aortic Global Endovascular Registry

Multi-arm, multi-center, open label, prospective observational registry designed to obtain safety and performance data on the use of CE marked and custom Terumo Aortic endovascular grafts.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Imeldaziekenhuis, Bonheiden, Belgium

Loading trial locations.

About this study

Post Market registry collecting real world, post-approval safety, performance, patient reported outcomes and health economic data on patients treated with Terumo Aortic endovascular stent-grafts in standard clinical practice.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Minimum age as per local regulations
  • Indication for aortic endovascular repair with an approved or CE marked by a Regulatory body or custom-made Terumo Aortic Endovascular graft
  • Ability to provide informed consent

o Emergent cases (typically younger patients with traumatic injuries) are not excluded if there is IRB/EC agreement to allow consent after intervention (i.e. consent to study participation, not to treatment) or use of a Legally Authorized Representative (LAR).

  • Willingness to comply with the registry protocol
  • Willingness to adhere to follow-up visits Note: Patients currently enrolled and actively participating within the TREO registry (IP-0020-16) can have their data migrated from TREO to the TiGER registry where local EC approval has been obtained and the patient has been reconsented to TiGER for longer follow-up.

Exclusion criteria

Patient is unable or unwilling to comply with the study follow-up regime. Patient is contraindicated per the IFU, or has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving treatment as well as the procedures and evaluations pre and post procedure.

Treatment and study plan

Thoracic

Device

Implant of a Relay stent graft system

Abdominal

Device

Implant with an Anaconda or Treo Stent graft system

Custom Device

Device

Implant of a Fenestrated device such as Fenestrated Anaconda or Fenestrated TREO, Relay Branch or other customised device

Illiac Artery

Device

Implant with an Anaconda Iliac leg only

Primary outcomes

  1. Aortic Related Mortality

    Time frame: 30 days post implant

    Defined as any death occurring within 30 days of implant, due to rupture or following any procedure intended to treat the target lesion

Secondary outcomes

  1. Technical Success

    Time frame: Day 0

    defined as:

    Successful delivery of the device through the vasculature (i.e. ability to deliver the implant to the intended location without the need for unanticipated corrective intervention related to delivery).

    Deployment of the endovascular stent-graft in the planned location with coverage of the target lesion (or entry tear in the case of dissection);Absence of unplanned coverage or aortic branch vessels; Patency of the endovascular stent-graft, absence of device deformations (e.g. kinks, stent eversion, maldeployment, misaligned deployment) requiring unplanned placement of an additional device within the endovascular stentgraft, and;Successful withdrawal (i.e. successful withdrawal of the delivery system, without the need for unanticipated corrective intervention related to withdrawal). Absence of Type Ia, Type Ib, Type IIIa and IIIb endoleak that extends beyond 30 days by confirmatory imaging (CTA, magnetic resonance angiography [MRA], or duplex ultrasound).

  2. Composite Clinical Success

    Time frame: 1 year

    defined as the absence of: Target lesion related mortality Type Ia, Ib, IIIa and IIIb endoleak Graft infection Stent patency <50% Target lesion aortic rupture Conversion to open repair Arrest of the original pathological process (e.g., total aortic diameter expansion >5 mm in the aorta that has a study endograft, embolization from penetrating ulcer, extension of dissection, false lumen perfusion) or a new aortic pathology as a result of the intervention (e.g., pseudoaneurysm, dissection, intramural hematoma, unintentional adverse dissection septum rupture, stent-graft induced aortic wall injury, new aortobronchial/tracheal or aortoenteric fistula formation)

  3. Additional Endpoints

    Time frame: 1 year

    All-cause mortality Safety (MAEs, all related adverse events) Target lesion reintervention, all secondary interventions Device performance based on imaging assessments of all morphological variables (aortic remodeling, all endoleaks, any loss of patency, stent-graft migration, device integrity, etc.)

Other outcomes

  1. Patient Outcome measure

    Time frame: 1 Year

    • Post-operative return to normal activities - employment, household activities, social life and hobbies (return to normal activities will be recorded at one year visit only)
  2. Health Economics

    Time frame: From Procedure to 1 Year

    The following health economic will also be summarized:

    Total procedure time (mins) Fluoroscopy time (mins) Blood loss (ml) Blood transfusion required (ml) Time in ICU (hours/mins) Time to hospital discharge (days) Total Procedure time (mins) Total anesthesia time (hours) Total Procedure to discharge time (hours/days)

  3. Health Economics

    Time frame: Day 0

    The following health economic will also be summarized:

    Arterial access route and type (Percutaneous or Cut down)

  4. Health Economics

    Time frame: Day 0

    The following health economic will also be summarized:

    Volume of contrast media used Volume of Blood loss Volume of Blood transfusion required

  5. Health Economics

    Time frame: Day 0

    The following health economic will also be summarized:

    Type of Image fusion technology used Type of Magnet system used

Study contacts

Contact information is provided by the study sponsor or research team.

Michelle Durnan

CONTACT

[email protected]

+44 141 343 0195

Sammy Jassal

CONTACT

[email protected]

+44 141 343 0195

Sponsors and collaborators

Lead sponsor

Vascutek Ltd.

Industry

Collaborators

  • Bolton Medical

Registry information

Official study title

A Global Post Market Evaluation of Terumo Aortic Endovascular Grafts

Acronym: TiGER

Important dates

Study start
2019
Primary completion
2029
Study completion
2030
First posted
Jan 29, 2020
Registry last updated
Mar 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.